WO1998052617A3 - Contrast media for imaging of lung draining lymph nodes, administered through the lungs - Google Patents

Contrast media for imaging of lung draining lymph nodes, administered through the lungs Download PDF

Info

Publication number
WO1998052617A3
WO1998052617A3 PCT/GB1998/001489 GB9801489W WO9852617A3 WO 1998052617 A3 WO1998052617 A3 WO 1998052617A3 GB 9801489 W GB9801489 W GB 9801489W WO 9852617 A3 WO9852617 A3 WO 9852617A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymph nodes
imaging
contrast media
lungs
administered
Prior art date
Application number
PCT/GB1998/001489
Other languages
French (fr)
Other versions
WO1998052617A2 (en
Inventor
Gregory Lynn Mcintire
John Luke Toner
Edward Richard Bacon
Patrick Joseph Hayley
Original Assignee
Nycomed Imaging As
Gregory Lynn Mcintire
John Luke Toner
Edward Richard Bacon
Patrick Joseph Hayley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As, Gregory Lynn Mcintire, John Luke Toner, Edward Richard Bacon, Patrick Joseph Hayley filed Critical Nycomed Imaging As
Priority to EP98922945A priority Critical patent/EP0975372A1/en
Priority to AU75405/98A priority patent/AU7540598A/en
Priority to JP55013898A priority patent/JP2001525846A/en
Publication of WO1998052617A2 publication Critical patent/WO1998052617A2/en
Publication of WO1998052617A3 publication Critical patent/WO1998052617A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests

Abstract

The invention relates to the use of particulate contrast media in the in vivo imaging of lung draining lymph nodes, e.g. to stage lung cancer patients.
PCT/GB1998/001489 1997-05-22 1998-05-22 Contrast media for imaging of lung draining lymph nodes, administered through the lungs WO1998052617A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98922945A EP0975372A1 (en) 1997-05-22 1998-05-22 Contrast media for imaging of lung draining lymph nodes, administered through the lungs
AU75405/98A AU7540598A (en) 1997-05-22 1998-05-22 Contrast media
JP55013898A JP2001525846A (en) 1997-05-22 1998-05-22 Contrast agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9710604.1 1997-05-22
GBGB9710604.1A GB9710604D0 (en) 1997-05-22 1997-05-22 Contrast media
US4917497P 1997-06-09 1997-06-09

Publications (2)

Publication Number Publication Date
WO1998052617A2 WO1998052617A2 (en) 1998-11-26
WO1998052617A3 true WO1998052617A3 (en) 1999-08-12

Family

ID=10812900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/001489 WO1998052617A2 (en) 1997-05-22 1998-05-22 Contrast media for imaging of lung draining lymph nodes, administered through the lungs

Country Status (5)

Country Link
EP (1) EP0975372A1 (en)
JP (1) JP2001525846A (en)
AU (1) AU7540598A (en)
GB (1) GB9710604D0 (en)
WO (1) WO1998052617A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9380998B2 (en) 1998-12-24 2016-07-05 Devicor Medical Products, Inc. Subcutaneous cavity marking device and method

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1304085A3 (en) 1994-09-16 2004-01-21 Ethicon Endo-Surgery, Inc. Biodegradable tissue marking device
US6371904B1 (en) 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US9669113B1 (en) 1998-12-24 2017-06-06 Devicor Medical Products, Inc. Device and method for safe location and marking of a biopsy cavity
GB0123013D0 (en) * 2001-09-25 2001-11-14 Upperton Ltd Improvements relating to imaging contrast agents

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911690A (en) * 1985-03-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment or diagnosis by endoscopic administration into the lymphatics
EP0387154A1 (en) * 1989-03-08 1990-09-12 Pierre Fabre Medicament Aerosol compositions for the imaging, diagnosis and targetted therapy of inflamed and tumoral focuses
EP0498482A2 (en) * 1991-01-25 1992-08-12 NanoSystems L.L.C. X-ray contrast compositions useful in medical imaging
EP0602691A2 (en) * 1992-12-15 1994-06-22 NanoSystems L.L.C. Controlled precipitation of particulate diagnostic imaging contrast agents
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
WO1997013503A1 (en) * 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911690A (en) * 1985-03-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment or diagnosis by endoscopic administration into the lymphatics
EP0387154A1 (en) * 1989-03-08 1990-09-12 Pierre Fabre Medicament Aerosol compositions for the imaging, diagnosis and targetted therapy of inflamed and tumoral focuses
EP0498482A2 (en) * 1991-01-25 1992-08-12 NanoSystems L.L.C. X-ray contrast compositions useful in medical imaging
EP0602691A2 (en) * 1992-12-15 1994-06-22 NanoSystems L.L.C. Controlled precipitation of particulate diagnostic imaging contrast agents
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
WO1997013503A1 (en) * 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BORCHARDT, G. ET AL: "Body distribution of 75Se-radiolabeled silica nanoparticles covalently coated with.omega.-functionalized surfactants after intravenous injection in rats", J. DRUG TARGETING, 1994, VOL. 2, NO. 1, PAGES 61-77, XP002083903 *
DAVIS S S: "Biomedical applications of nanotechnology - implications for drug targeting and gene therapy", TRENDS IN BIOTECHNOLOGY, vol. 15, no. 6, June 1997 (1997-06-01), pages 217-224, XP004064510 *
MORGAN HK ET AL: "Inhalation of 2,3,5-triiodobenzoic acid by normal and sulfur dioxide-exposed rats.", J PHARM SCI, NOV 1974, VOL. 63, NO. 11, PAGE(S) 1759-61, XP002083902 *
THIELE J ET AL: "Computerized tomography measurement of lung ventilation by inhalation of Isovist-300]", RONTGENPRAXIS, SEP 1995, VOL. 48, NO. 9, PAGE(S) 259-60, XP002083900 *
WENZEL-HORA BI ET AL: "Iotasul, a water-soluble (non-oily) contrast medium for direct and indirect lymphography: radiological and morphological investigations in dogs.", LYMPHOLOGY, SEP 1981, VOL. 14, NO. 3, PAGE(S) 101-12, XP002083901 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9380998B2 (en) 1998-12-24 2016-07-05 Devicor Medical Products, Inc. Subcutaneous cavity marking device and method

Also Published As

Publication number Publication date
JP2001525846A (en) 2001-12-11
WO1998052617A2 (en) 1998-11-26
EP0975372A1 (en) 2000-02-02
GB9710604D0 (en) 1997-07-16
AU7540598A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
ZA99693B (en) Compounds for therapy and diagnosis of lung cancer and methods for their use.
HUP0201757A3 (en) Compositoins and methods for the therapy and diagnosis of lung cancer
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001257620A1 (en) Supplemental heart pump methods and systems for supplementing blood through the heart
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU4185100A (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
HUP0200760A2 (en) Compounds and methods for therapy and diagnosis of lung cancer
HK1070080A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
WO1998052617A3 (en) Contrast media for imaging of lung draining lymph nodes, administered through the lungs
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU2001273127A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU4418400A (en) Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin
AU2002319080A1 (en) Method for the diagnosis and therapy of renal cell carcinoma
EP0755262A4 (en) Composition for the treatment of lung disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 550138

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09443345

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998922945

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998922945

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998922945

Country of ref document: EP